151. Bifidobacterium breveModulates Lactic Acid to Curtail Escherichia coliExpansion and Alleviate Inflammatory Bowel Disease
- Author
-
Gao, Xiaoxiang, Xia, Yuxuan, Sun, Xiaoxuan, Dou, Wenxuan, Chen, Ruimin, Huang, Pan, Yu, Leilei, Tian, Fengwei, Zhao, Jianxin, Chen, Wei, and Zhai, Qixiao
- Abstract
Inhibition of the abnormal proliferation of Escherichia coliis crucial for alleviating inflammatory bowel disease. Due to the complexity of the gut microbiota, specifically targeting and inhibiting particular microbes is a challenging task. One approach involves screening for probiotics that antagonize E. coli; however, this process often requires extensive in vitroexperiments using a vast pool of probiotics. In this study, we employed a genome-scale metabolic prediction model to predict the interactions between 803 strains of microbes and E. coli. The results indicated that Bifidobacterium breveand Bifidobacterium animalisexhibited the most potent inhibitory effects. In vitroantibacterial assays and mouse experiments validated the inhibitory efficacy of B. breveCCFM1369. Additionally, B. breveCCFM1369 demonstrated the ability to inhibit key gene Ldhaand HIF-2αand reduce the luminal lactate concentration, thereby diminishing the colonization capacity of E. coli. These findings support the potential application of B. brevein the alleviation of colitis.
- Published
- 2024
- Full Text
- View/download PDF